Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc.
Gain Therapeutics reports Q1 2025 financial results, progressing Phase 1b study of Parkinson's treatment GT-02287, with FDA engagement anticipated. Successful administration of GT-02287, a lead drug ...
Hosted on MSN
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development
At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc. (NASDAQ:GANX) unveiled new preclinical data on its lead drug candidate, GT-02287. GT-02287, a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results